Wed, August 8, 2012
Tue, August 7, 2012
Mon, August 6, 2012
Fri, August 3, 2012
Thu, August 2, 2012
[ Thu, Aug 02nd 2012 ]: Market Wire
00 p.m. EDT
Wed, August 1, 2012
[ Wed, Aug 01st 2012 ]: Market Wire
Head of European Operations
Tue, July 31, 2012
Mon, July 30, 2012
Sun, July 29, 2012
Fri, July 27, 2012
Thu, July 26, 2012
Wed, July 25, 2012
Tue, July 24, 2012
Mon, July 23, 2012
Sun, July 22, 2012
Sat, July 21, 2012
Fri, July 20, 2012
Thu, July 19, 2012
Wed, July 18, 2012
Tue, July 17, 2012
Mon, July 16, 2012
[ Mon, Jul 16th 2012 ]: Market Wire
30 a.m. ET
Fri, July 13, 2012
Thu, July 12, 2012

DURECT Corporation Invites You to Join its Second Quarter 2012 Earnings Conference Call


  Copy link into your clipboard //health-fitness.news-articles.net/content/2012/ .. econd-quarter-2012-earnings-conference-call.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

DURECT Corporation Invites You to Join its Second Quarter 2012 Earnings Conference... -- CUPERTINO, Calif., July 26, 2012 /PRNewswire/ --

DURECT Corporation Invites You to Join its Second Quarter 2012 Earnings Conference Call

[ ]
[ ]

CUPERTINO, Calif., July 26, 2012 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: [ DRRX ]) second quarter 2012 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, August 6, 2012 at 4:30 pm Eastern Time (1:30 pm Pacific Time).

(Logo: [ http://photos.prnewswire.com/prnh/20020717/DRRXLOGO ])

A live audio webcast of the presentation will be available by accessing DURECT's homepage at [ http://www.durect.com ] and clicking "Investor Relations."  If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR, ELADUR®, and TRANSDUR®-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies may enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit [ www.durect.com ].

NOTE: POSIDUR, SABER®, ORADUR®, TRANSDUR®, and ELADUR® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

SOURCE DURECT Corporation



[ Back to top ]

RELATED LINKS
[ http://www.durect.com ]


Publication Contributing Sources